LENZ Therapeutics, Inc. (LENZ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 5M 10M 15M Q2 '24: 0 Q3 '24: 0 Q1 '25: 0 Q2 '25: 5M Q3 '25: 12.5M Q4 '25: 1.6M Q1 '26: 1.9M Q2 '26: 5.5M Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 2M 4M 6M Q1 '25: 0 Q2 '25: 5M Q1 '26: 825K Q2 '26: 5.2M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -14.6M Q4 '21: -18.9M Q1 '22: -26M Q2 '22: -26.8M Q3 '22: -26.2M Q4 '22: -26.8M Q1 '23: -12.6M Q2 '23: -15M Q3 '23: -19.9M Q4 '23: -25M Q1 '24: -16.1M Q2 '24: -14.4M Q3 '24: -12.9M Q4 '24: -15.2M Q1 '25: -16.9M Q2 '25: -16.9M Q3 '25: -18.9M Q4 '25: -38.5M Q1 '26: -44.1M Q2 '26: -34.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -14.6M Q4 '21: -18.9M Q1 '22: -25.8M Q2 '22: -25.9M Q3 '22: -24.7M Q4 '22: -24.6M Q1 '23: -12.7M Q2 '23: -14.7M Q3 '23: -18.9M Q4 '23: -23.7M Q1 '24: -16.6M Q2 '24: -10.3M Q3 '24: -10.2M Q4 '24: -12.7M Q1 '25: -14.6M Q2 '25: -14.9M Q3 '25: -16.7M Q4 '25: -35.9M Q1 '26: -41.5M Q2 '26: -31.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 400K 800K 1.2M Q1 '25: 0 Q2 '25: 0 Q1 '26: 1.1M Q2 '26: 280K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -15.4M Q4 '21: -15.6M Q1 '22: -21.2M Q2 '22: -22.1M Q3 '22: -22.2M Q4 '22: -22.4M Q1 '23: -12.8M Q2 '23: -13.5M Q3 '23: -13.1M Q4 '23: -21M Q1 '24: -23.9M Q2 '24: -15.8M Q3 '24: -10.6M Q4 '24: -9.1M Q1 '25: -16M Q2 '25: -11.5M Q3 '25: -8.6M Q4 '25: -33M Q1 '26: -33.6M Q2 '26: -38.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -19.1M Q4 '21: -16.6M Q1 '22: -24.5M Q2 '22: -23.5M Q3 '22: -23.1M Q4 '22: -23.4M Q1 '23: -12.8M Q2 '23: -13.5M Q3 '23: -13.1M Q4 '23: -21M Q1 '24: -23.9M Q2 '24: -15.9M Q3 '24: -10.8M Q4 '24: -9.2M Q1 '25: -16.2M Q2 '25: -11.7M Q3 '25: -9M Q4 '25: -33.1M Q1 '26: -33.6M Q2 '26: -38.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '21: 5.1M Q3 '21: 52.8M Q1 '22: 54M Q2 '22: 54.6M Q3 '22: 55.2M Q1 '23: 2M Q2 '23: 2M Q3 '23: 2M Q1 '24: 4.7M Q2 '24: 25.6M Q3 '24: 27.2M Q1 '25: 27.5M Q2 '25: 28.1M Q3 '25: 28.5M Q1 '26: 31.4M Q2 '26: 31.4M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '20: -29.93 Q1 '21: -34.71 Q2 '21: -37.60 Q3 '21: -36.88 Q4 '21: -2.45 Q1 '22: 2.82 Q2 '22: 5.79 Q3 '22: 5.62 Q4 '22: -1.85 Q1 '23: -7.87 Q2 '23: -14.92 Q3 '23: -24.09 Q4 '23: -35.70 Q1 '24: -32.73 Q2 '24: -25.60 Q3 '24: -16.36 Q4 '25: -2.85 Q1 '26: -3.64 Q2 '26: -4.13 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.